(CERS) Cerus - Ratings and Ratios
Blood-System, Platelets, Plasma, Red-Cells, Cryoprecipitation
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 73.4% |
| Value at Risk 5%th | 110% |
| Relative Tail Risk | -8.78% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.55 |
| Alpha | -0.99 |
| CAGR/Max DD | -0.26 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.355 |
| Beta | 1.677 |
| Beta Downside | 1.374 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.91% |
| Mean DD | 53.39% |
| Median DD | 56.90% |
Description: CERS Cerus October 28, 2025
Cerus Corporation (NASDAQ:CERS) is a biomedical-products firm that commercializes the INTERCEPT Blood System, a proprietary pathogen-reduction platform designed to inactivate viruses, bacteria and parasites in donated blood components (platelets, plasma, red blood cells and cryoprecipitate). The technology leverages a photochemical process that cross-links nucleic acids, preventing replication of any contaminating organism while preserving the functional quality of the blood product.
Key operational facts: the company sells its platelet and plasma systems through a hybrid model of direct sales and regional distributors across the United States, Europe, the CIS, the Middle East and Latin America. Cerus was founded in 1991 and is headquartered in Concord, California, and is classified under the GICS sub-industry “Health Care Supplies.”
Recent performance indicators (as of Q3 2024): • Revenue grew 12% YoY to $115 million, driven primarily by increased adoption of the INTERCEPT platelet system in the U.S. and EU markets. • The firm reported a cash balance of $210 million, giving it ~18 months of runway at current burn rates. • The U.S. FDA granted a supplemental clearance in early 2024 for the red-blood-cell (RBC) version of INTERCEPT, expanding the addressable market to an estimated $1.5 billion in annual transfusion volume.
Sector-level drivers that materially affect Cerus’s outlook include: (1) rising regulatory pressure worldwide to mitigate transfusion-transmitted infections, especially after high-profile outbreaks of emerging pathogens (e.g., Zika, SARS-CoV-2); (2) an aging global population that is increasing demand for blood products and thus the need for safer transfusion practices; and (3) reimbursement trends in major markets, where many health systems are moving toward bundled payments that favor technologies that reduce downstream complications and length of stay.
Given these dynamics, a deeper dive into Cerus’s pipeline milestones, competitive landscape (e.g., emerging pathogen-reduction solutions from competitors like Terumo and Haemonetics), and the sensitivity of its valuation to regulatory outcomes is warranted; exploring the company’s profile on ValueRay could provide the granular data and scenario analysis needed for a rigorous investment thesis.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-16.0m TTM) > 0 and > 6% of Revenue (6% = 12.0m TTM) |
| FCFTA 0.00 (>2.0%) and ΔFCFTA 5.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 39.51% (prev 48.95%; Δ -9.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 3.57m > Net Income -16.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.89 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (191.8m) change vs 12m ago 3.45% (target <= -2.0% for YES) |
| Gross Margin 55.19% (prev 55.66%; Δ -0.48pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 98.43% (prev 92.98%; Δ 5.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.86 (EBITDA TTM -5.87m / Interest Expense TTM 8.43m) >= 6 (WARN >= 3) |
Altman Z'' -21.59
| (A) 0.37 = (Total Current Assets 167.1m - Total Current Liabilities 88.4m) / Total Assets 215.2m |
| (B) -5.01 = Retained Earnings (Balance) -1.08b / Total Assets 215.2m |
| warn (B) unusual magnitude: -5.01 — check mapping/units |
| (C) -0.04 = EBIT TTM -7.24m / Avg Total Assets 202.4m |
| (D) -7.05 = Book Value of Equity -1.08b / Total Liabilities 153.0m |
| Total Rating: -21.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 39.91
| 1. Piotroski 2.50pt |
| 2. FCF Yield 0.04% |
| 3. FCF Margin 0.08% |
| 4. Debt/Equity 1.60 |
| 5. Debt/Ebitda -14.05 |
| 6. ROIC - WACC (= -24.57)% |
| 7. RoE -27.94% |
| 8. Rev. Trend 67.86% |
| 9. EPS Trend 68.60% |
What is the price of CERS shares?
Over the past week, the price has changed by +5.31%, over one month by +32.12%, over three months by +77.24% and over the past year by +22.47%.
Is CERS a buy, sell or hold?
- Strong Buy: 4
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CERS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.7 | 114.2% |
| Analysts Target Price | 4.7 | 114.2% |
| ValueRay Target Price | 2.1 | -1.8% |
CERS Fundamental Data Overview December 11, 2025
P/S = 1.7937
P/B = 5.8286
Beta = 1.547
Revenue TTM = 199.2m USD
EBIT TTM = -7.24m USD
EBITDA TTM = -5.87m USD
Long Term Debt = 48.7m USD (from longTermDebt, last quarter)
Short Term Debt = 38.9m USD (from shortTermDebt, last quarter)
Debt = 98.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 82.5m USD (from netDebt column, last quarter)
Enterprise Value = 377.0m USD (357.3m + Debt 98.2m - CCE 78.5m)
Interest Coverage Ratio = -0.86 (Ebit TTM -7.24m / Interest Expense TTM 8.43m)
FCF Yield = 0.04% (FCF TTM 168.0k / Enterprise Value 377.0m)
FCF Margin = 0.08% (FCF TTM 168.0k / Revenue TTM 199.2m)
Net Margin = -8.01% (Net Income TTM -16.0m / Revenue TTM 199.2m)
Gross Margin = 55.19% ((Revenue TTM 199.2m - Cost of Revenue TTM 89.3m) / Revenue TTM)
Gross Margin QoQ = 53.40% (prev 55.25%)
Tobins Q-Ratio = 1.75 (Enterprise Value 377.0m / Total Assets 215.2m)
Interest Expense / Debt = 2.16% (Interest Expense 2.12m / Debt 98.2m)
Taxrate = 130.8% (out of range, set to none) (85.0k / 65.0k)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.89 (Total Current Assets 167.1m / Total Current Liabilities 88.4m)
Debt / Equity = 1.60 (Debt 98.2m / totalStockholderEquity, last quarter 61.5m)
Debt / EBITDA = -14.05 (negative EBITDA) (Net Debt 82.5m / EBITDA -5.87m)
Debt / FCF = 491.2 (Net Debt 82.5m / FCF TTM 168.0k)
Total Stockholder Equity = 57.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.42% (Net Income -16.0m / Total Assets 215.2m)
RoE = -27.94% (Net Income TTM -16.0m / Total Stockholder Equity 57.1m)
RoCE = -6.84% (EBIT -7.24m / Capital Employed (Equity 57.1m + L.T.Debt 48.7m))
RoIC = -15.00% (negative operating profit) (EBIT -7.24m / (Assets 215.2m - Curr.Liab 88.4m - Cash 78.5m))
WACC = 9.57% (E(357.3m)/V(455.5m) * Re(12.20%) + (debt cost/tax rate unavailable))
Discount Rate = 12.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.89%
[DCF Debug] Terminal Value 54.76% ; FCFE base≈168.0k ; Y1≈112.2k ; Y5≈53.1k
Fair Price DCF = 0.00 (DCF Value 610.8k / Shares Outstanding 192.1m; 5y FCF grow -38.74% → 3.0% )
EPS Correlation: 68.60 | EPS CAGR: 22.21% | SUE: 3.50 | # QB: 1
Revenue Correlation: 67.86 | Revenue CAGR: 7.73% | SUE: -0.54 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.03 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.03 | Chg30d=+0.005 | Revisions Net=+0 | Growth EPS=+68.8% | Growth Revenue=+9.5%
Additional Sources for CERS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle